Pamrevlumab

Drug Profile

Pamrevlumab

Alternative Names: Anti-CTGF antibody; FG-3019

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Pancreatic cancer
  • Phase I Glomerulonephritis
  • Preclinical Glioblastoma
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies

Most Recent Events

  • 13 Sep 2017 Efficacy and safety data from a phase IIb trial in Idiopathic pulmonary fibrosis presented at the European Respiratory Society (ERS) International Congress 2017 (ERS-2017)
  • 07 Aug 2017 Adverse events and efficacy data from a phase II trial in Idiopathic pulmonary fibrosis released by FibroGen
  • 21 Jun 2017 FibroGen completes a phase II trial in Idiopathic pulmonary fibrosis in USA (NCT01262001)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top